Prognostic value of plasma levels of thrombomodulin and von Willebrand factor in Egyptian children with acute lymphoblastic leukemia

被引:15
作者
Hagag, Adel A. E.
Abdel-Lateef, Amal E.
Aly, Rabab
机构
[1] Department of Pediatrics, Tanta University Hospital, Elemam Muslim from El Helw Street, No. 16, Tanta
[2] Department of Clinical Pathology, Tanta University
[3] Department of Clinical Pathology, Mansoura University
关键词
Childhood malignancies; acute lymphoblastic leukemia; thrombomodulin; vascular endothelium; von Willebrand factor;
D O I
10.1177/1078155213508439
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Acute lymphoblastic leukemia is the most common childhood malignancies, representing nearly one-third of all pediatric cancers. Thrombomodulin is a membrane glycoprotein in the vascular endothelium. Its plasma level depends on the integrity of the endothelium. Soluble thrombomodulin is derived from injured endothelial cells or proteolytically cleaved from thrombomodulin by proteases. Von Willebrand factor is a blood glycoprotein involved in homeostasis. Its plasma level increases in neoplastic diseases and arises from adverse changes in the endothelium. Severe endothelial dysfunction is present during the acute phase of acute lymphoblastic leukemia. Plasma levels of von Willebrand factor and soluble thrombomodulin have been used as indexes of endothelial dysfunction. Objective: The aim of this study was to assess serum soluble thrombomodulin and von Willebrand factor levels in children with acute lymphoblastic leukemia during acute phase of the disease to assess their potential prognostic value. Patients and methods: Forty patients with acute lymphoblastic leukemia included 26 males and 14 females with their ages ranged from 2 to 10 years and 20 healthy children of matched age and sex were included in this study. We analyzed serum soluble thrombomodulin and von Willebrand factor levels by enzyme-linked immunosorbent assay. Results: In children with acute lymphoblastic leukemia, there was a significant increase in soluble thrombomodulin, and von Willebrand factor levels during the acute phase of the disease. Children with an unfavorable outcome had higher levels of thrombomodulin and von Willebrand factor levels. Conclusions: Serum thrombomodulin and von Willebrand factor levels as a parameter of endothelial dysfunction during the acute phase of acute lymphoblastic leukemia might represent an additional prognostic marker in childhood acute lymphoblastic leukemia.
引用
收藏
页码:356 / 361
页数:6
相关论文
共 20 条
[1]  
Ribera J.M., Oriol A., Acute lymphoblastic leukemia in adolescents and young adults, Hematol Oncol Clin North Am, 23, pp. 1033-1042, (2009)
[2]  
Pui C.H., Evans W.E., Treatment of acute lymphoblastic leukemia, N Eng J Med, 354, pp. 166-178, (2006)
[3]  
Moricke A., Reiter A., Zimmermann M., Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95, Blood, 111, pp. 4477-4489, (2008)
[4]  
Moghrabi A., Levy D.E., Asselin B., Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia, Blood, 109, pp. 896-904, (2007)
[5]  
Pui C.H., Campana D., Pei D., Treating childhood acute lymphoblastic leukemia without cranial irradiation, N Engl J Med, 360, pp. 2730-2741, (2009)
[6]  
Veerman A.J., Kamps W.A., Van Den Berg H., Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004), Lancet Oncol, 10, pp. 957-966, (2009)
[7]  
Hunger S.P., Lu X., Devidas M., Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children's oncology group, J Clin Oncol, 30, pp. 1663-1669, (2012)
[8]  
Kulwas A., Szaflarska S.A., Czerwionka S.M., Et al., Von Willebrand factor and thrombomodulin as markers of endothelial cell functions in children with chronic viral hepatitis, Med Wieku Rozwoj, 8, pp. 107-114, (2004)
[9]  
Li Y.H., Kuo C.H., Shi G.Y., The role of thrombomodulin lectin-like domain in inflammation, J Biomed Sci, 19, pp. 34-34, (2012)
[10]  
Califano F., Giovanniello T., Pantone P., Clinical importance of thrombomodulin serum levels, Eur Rev Med Pharmacol Sci, 4, pp. 59-66, (2000)